Feb22 event *remove after event end

Gain Therapeutics' 2024 R&D update with KOL and Analyst Insight

Register Here >>

subpage banner

Posters single page

20th Annual WORLDSymposium®

GT-02287, a clinical stage GCase enhancer, displays neuroprotection and restores motor function in preclinical models of Parkinson’s disease following delayed administration

2023 International Congress of Parkinson's Disease and Movement Disorders®

GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson’s disease

2023 International Congress of Parkinson's Disease and Movement Disorders®

Neuroprotective effect of GT-02287, a brain-penetrant structurally targeted allosteric regulator of glucocerebrosidase, leads to a significant reduction of plasma NfL levels and improvement in behavioural deficits in a mouse model of GBA1 Parkinson’s dise

2023 Gordon Research Conference on Lysosomal Diseases

Identification of novel allosteric β-galactosidase regulators that prevent GM1 ganglioside accumulation

Scientific Conference: AD/PD 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and...

Small-Molecule Structurally Targeted Allosteric Regulators Of Glucocerebrosidase Show Neuroprotective Properties In Cell-Based Models Of Alzheimer’s Disease

19th annual WORLDSymposium (2023)

GT-02329, a structurally targeted allosteric regulator of GCase, restores GCase activity, reduces microgliosis and improves fine locomotor skills in the CBE model of neuronopathic Gaucher’s disease

2022 SYNUCLEIN MEETING

Targeting glucocerebrosidase with structurally targeted allosteric regulators corrects abnormal phenotypes in models of Parkinson’s disease

XXVII World Congress on Parkinson’s Disease and Related Disorders

GT-02287, a Brain-Penetrant Structurally Targeted Allosteric Regulator for Glucocerebrosidase Shows Evidence of Pharmacological Efficacy in Models of Parkinson’s Disease

International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting

GT-02287, A Brain-penetrant Structurally Targeted Allosteric Regulator of Glucocerebrosidase Shows Evidence of Pharmacological Efficacy in Conduritol β-epoxide (CBE) Models of Parkinson’s Disease

2022 GLYCOLIPID AND SPHINGOLIPID BIOLOGY GRC

Structurally targeted allosteric regulators show promising therapeutic effect in Gaucher Disease cortical neurons

AD/PD™ 2022​ International Conference on Alzheimer's and Parkinson's Diseases

Brain-penetrant structurally targeted allosteric regulators for glucocerebrosidase (GCase) show promising pharmacological activity in models of neurodegenerative diseases

18th Annual WORLDSymposium (2022)

Development of structurally targeted allosteric regulators for the treatment of neuronopathic Gaucher disease

World Congress on Parkinson’s Disease and Related Disorders 2021

Preclinical development of brain-penetrant structurally targeted allosteric regulators for the treatment of GBA1 Parkinson’s disease and related alpha-synucleopathies

WORLDSymposium 2021

Insights into the mechanism of action of structurally targeted allosteric regulators for the treatment of Gaucher disease

WORLDSymposium 2021

Preclinical development of brain-penetrant structurally targeted allosteric regulators for the treatment of neuronopathic Gaucher disease

WORLDSymposium 2021

Insights into the mechanism of action of structurally targeted allosteric regulators for the treatment of GLB1-related disorders

Keystone Symposia 2020 - Brain Therapeutics

Correcting protein misfolding with Structurally Targeted Allosteric Regulators: Applications in rare diseases and brain therapeutics

WorldSymposium 2020

Allosteric regulators improving biodistribution of recombinant laronidase in Mucopolysaccharidosis type 1 (MPS1)

WorldSymposium 2020

Brain Penetrant Structurally Targeted Allosteric Regulators for Treating GLB1-Related Disorders

Synuclein Meeting 2019

Brain penetrant structurally targeted allosteric regulators for treating Parkinson disease and other α-synucleinopathies